AI

BPI 2026 · Large pharma

Astellas Institute for Regenerative Medicine at BPI 2026

Astellas Institute for Regenerative Medicine brings 2 presentations to BPI 2026 in Boston. Its sessions look at cell and gene therapy strategy, from large pharma investment priorities to phase-appropriate manufacturing designed with the end in mind.

OrganizationBPI 2026 Attendance
AI
Astellas Institute for Regenerative Medicine
1 Head of Cell & Gene Therapy Research · 1 Team Lead, Drug Product Development, CMC-Tech Ops
Large pharma
Astellas subsidiary researching and developing pluripotent stem cell-derived cell therapies.
Keynote
Wed Sep 23
2:00pm–2:40pm
Keynote Panel Discussion- Big Pharma’s Cell and Gene Therapies Wish List: Investment Priorities and Emerging Opportunities
Cell & Gene Keynote Plenary · with Kite Pharma, Dark Horse Consulting
Talk
Thu Sep 24
4:30pm–5:30pm
Panel Discussion: Starting with the End in Mind: Designing Smart and Phase Appropriate Manufacturing for Successful Cell and Gene Therapy Development
Development of Emerging Cell & Gene Therapies · with Mill Creek Consulting, Ultragenyx, Genetix Biotherapeutics

Explore the full BPI 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full BPI 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Astellas Institute for Regenerative Medicine

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Informa Connect or the BioProcess International Conference & Exhibition. Submit a correction